An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.
The Food and Drug Administration has approved a change to the label of a Novo Nordisk drug stating that it offers superior blood-sugar control to a competing drug made by Merck, based on results of two clinical studies, Novo Nordisk said Monday.
Self-monitoring blood glucose levels in Type 2 diabetics not on an insulin regimen may contribute little to managing the disease, according to an analysis published online last month by The Cochran Library.
A diabetes drug made by Bristol-Myers Squibb and AstraZeneca significantly reduced Type 2 diabetes patients' blood-sugar levels, compared with placebo, when added to insulin, according to results of a new study.
Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.
Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.
Patients with Type 1 diabetes using an insulin product made by Eli Lilly can store it in their pumps for longer periods of time, while children using it have additional options, thanks to a labeling change approved Wednesday by the Food and Drug Administration.
Diabetics that have trouble sleeping likely experience high insulin resistance and have a more difficult time controlling the disease, according to study findings published in the June issue of Diabetes Care.
A study published online in the journal Diabetes Care, and slated for the April print issue, suggested that counting carbohydrates could lead to an improvement in quality of life and a reduction in body mass index and waist circumference in patients with Type 1 diabetes who receive continuous subcutaneous insulin infusions.